Add to ORKG15Temozolomide is a well-tolerated alkylating agent, that is able to permeate the blood-brain barrier (BBB), and has additive cytotoxicity when given with radiotherapy (RT). A phase II trial assessing temozolomide 150 mg/m(2)/day, for 5 days every 28 days in primary central nervous system (CNS) lymphoma (PCNSL) patients with negative human immunodeficiency virus (HIV) serology, Eastern Cooperative Oncology Group (ECOG) performance status (PS)<4, previously treated with high-dose methotrexate-containing (HD-MTX) chemotherapy and/or RT was started. Twenty-three patients were enrolled. Median age was 60 years. Five complete remissions (median duration 6+ months; range 2-36 months), one partial response, four stable disease (median duration 7.2...
Purpose: In this phase II study (NCT00942747), temsirolimus was tested in patients with relapsed or ...
OBJECTIVE: We report updated results at a median follow-up of 12 years of a phase II trial assessing...
ObjectivesTo assess the results and toxicity of a regimen of combined chemotherapy and radiotherapy ...
Temozolomide is a well-tolerated alkylating agent, that is able to permeate the blood-brain barrier ...
18Methotrexate (MTX)-based chemotherapy extends survival in patients with primary brain lymphomas, b...
BACKGROUND: Oligodendroglial tumors are chemosensitive, with two-thirds of patients responding...
PURPOSE: Oligodendroglial tumors are chemotherapy-sensitive tumors, with two thirds of patients resp...
Introduction: The primary tumour type most likely to metastasize to the brain is lung cancer. In hea...
Purpose: To confirm the feasibility and estimate the efficacy of methotrexate (MTX), teniposide, car...
13Objective:We report updated results at a median follow-up of 12 years of a phase II trial assessin...
High-dose methotrexate (HD-MTX) is effective in the initial treatment of primary central nervous sys...
Objective:We report updated results at a median follow-up of 12 years of a phase II trial assessing ...
Introduction: The primary tumour type most likely to metastasize to the brain is lung cancer. In hea...
Primary CNS lymphoma (PCNSL) is an aggressive form of non-Hodgkin\u27s lymphoma that accounts for 3%...
PURPOSE: Temozolomide is a well-tolerated oral alkylating agent with activity in the CNS. A multicen...
Purpose: In this phase II study (NCT00942747), temsirolimus was tested in patients with relapsed or ...
OBJECTIVE: We report updated results at a median follow-up of 12 years of a phase II trial assessing...
ObjectivesTo assess the results and toxicity of a regimen of combined chemotherapy and radiotherapy ...
Temozolomide is a well-tolerated alkylating agent, that is able to permeate the blood-brain barrier ...
18Methotrexate (MTX)-based chemotherapy extends survival in patients with primary brain lymphomas, b...
BACKGROUND: Oligodendroglial tumors are chemosensitive, with two-thirds of patients responding...
PURPOSE: Oligodendroglial tumors are chemotherapy-sensitive tumors, with two thirds of patients resp...
Introduction: The primary tumour type most likely to metastasize to the brain is lung cancer. In hea...
Purpose: To confirm the feasibility and estimate the efficacy of methotrexate (MTX), teniposide, car...
13Objective:We report updated results at a median follow-up of 12 years of a phase II trial assessin...
High-dose methotrexate (HD-MTX) is effective in the initial treatment of primary central nervous sys...
Objective:We report updated results at a median follow-up of 12 years of a phase II trial assessing ...
Introduction: The primary tumour type most likely to metastasize to the brain is lung cancer. In hea...
Primary CNS lymphoma (PCNSL) is an aggressive form of non-Hodgkin\u27s lymphoma that accounts for 3%...
PURPOSE: Temozolomide is a well-tolerated oral alkylating agent with activity in the CNS. A multicen...
Purpose: In this phase II study (NCT00942747), temsirolimus was tested in patients with relapsed or ...
OBJECTIVE: We report updated results at a median follow-up of 12 years of a phase II trial assessing...
ObjectivesTo assess the results and toxicity of a regimen of combined chemotherapy and radiotherapy ...